DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.message sent
email sent successfully
rareLife solutions 606 Post Road East #397 Westport, CT 06880 |
||
You are receiving this because you have an account on www.oneSMAvoice.com | ||
If you'd like to unsubscribe and stop receiving these emails click here |
Trusted Resources: News & Meetings
Latest announcements and gatherings
A ‘Miracle’: Spinraza Gives Boy, Now 5, a Chance to Grow Up
It’s now been more than four years since Spinraza (nusinersen) was first approved by the U.S. Food and Drug Administration, and presymptomatic children with spinal muscular atrophy (SMA) who received the therapy as part of the Phase 2 NURTURE trial are growing up fast and, by all accounts, showing good progress.
Jase Yoder, 5, is one of those children. He was featured as part of “The Gene” documentary on PBS last year. In the segment, Jase, who has SMA type 1, can be seen jumping on a trampoline. Sitting up, walking, and jumping were all milestones Jase would have likely not achieved if it weren’t for Spinraza infusions. In fact, children with SMA type 1 typically don’t make it past the age of 2.


Related Content
-
News & MeetingsDespite Taking Spinraza, SMA Type 1 Children Show Nonmotor ProblemsDespite its well-reported benefits in mo...
-
News & MeetingsSafety and Efficacy Data Published for Novel Nusinersen Drug Delivery Method for Spinal Muscular Atrophy PatientsA recently published paper details the s...
-
News & MeetingsBiogen to Launch Study of Higher Spinraza Dose in Patients With Later Onset SMABiogen announced it intends to initiate ...
-
News & MeetingsBiogen Announces New Updates Across Its SMA Research Program at 2022 MDA ConferenceBiogen Inc. announced new data and updat...
-
Videos & VisualsSpinal Muscular Atrophy 2020: SMA Medications for Treatment Updateshttps://www.youtube.com/watch?v=dnSXnvrO...
-
Videos & VisualsSMA and Nusinersen (Spinraza) the Story so farhttps://slideplayer.com/slide/14664651/...
-
EducationComparison of Nusinersen and Evrysdi in the Treatment of Spinal Muscular AtrophySpinal Muscular Atrophy (SMA) is a genet...
send a message
Reset password
password changed successfully!

please log in with your email address and new password.
your activation key expired
this confirmation key has expired. please try to log in again or resend confirmation email.
confirmation email sent

a confirmation email has been sent to your inbox. click the link in the email to activate your account.
can't find the email? be sure to check your spam folder.
password reset email sent

an email has been sent to you with a link to reset your password.
can't find the email? be sure to check your spam folder.

If you are a doctor or other qualified health care professional, you should not offer any medical advice or treatment on our Sites, nor should you allow the content of our Sites to substitute for your own medical judgment. Please thoroughly review the information provided on our Sites before deciding whether any of the products, services, or treatments therein are right for you or others.
your account is now activated!

Log in
This feature is only available to members.
you haven't confirmed your email address yet. resend confirmation email